54 results
8-K
MIRM
Mirum Pharmaceuticals Inc
16 Jan 24
Departure of Directors or Certain Officers
4:15pm
Blood Therapeutics, Inc. from November 2014 through April 2020, including as vice president, program leadership and business strategy, senior vice … for the company’s technical operations, supply chain, program management and leadership, quality assurance and commercial strategy and analytics functions. From
8-K
EX-99.2
MIRM
Mirum Pharmaceuticals Inc
8 Jan 24
Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates
8:30am
strategy, objectives and opportunities, including as a result of our acquisition of CHOLBAM and CHENODAL and the anticipated benefits resulting from … Positioned to Execute on Our Strategy * Cash, cash equivalents and investments as of September 30, 2023.
Commercial Overview
Efficient Global Rare Disease
8-K
EX-99.1
2xge89fdip
13 Oct 23
Other Events
4:16pm
8-K
EX-99.1
6f7mk
5 Sep 23
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics
8:36am
8-K
EX-99.1
t0vkpbc4
17 Jul 23
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
8:16am
8-K
EX-99.2
lmb4idw
17 Jul 23
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
8:16am
8-K
EX-99.1
tmiacfott 0ep11a7o
9 Nov 22
Results of Operations and Financial Condition
7:30am
8-K
EX-99.2
by750xm66zz
24 Oct 22
Regulation FD Disclosure
8:46am
424B5
525tjyv
10 Aug 22
Prospectus supplement for primary offering
5:07pm
424B5
lsc291y3 m82
9 Aug 22
Prospectus supplement for primary offering
12:00am